In 2008, the FDA approved the clinical application of trastuzumab, which is a humanized monoclonal antibody directed against HER2.20 Trastuzumab was shown to improve survival for breast cancer patients with HER2 overexpression, especially when combined with standard chemotherapy or neoadjuvant chemotherapy,21, 22 suggesting that the prognosis of breast cancer patients could be elevated with the aid of appropriate treatment. Here, ERBB2 is linked to breast carcinoma.